Drug Search Results
More Filters [+]

HEC-68498

Alternative Names: hec-68498, hec68498, hec 68498
Latest Update: 2022-08-12
Latest Update Note: Clinical Trial Update

Product Description

HEC 68498 is an oral inhibitor of phosphatidylinositol 3-kinase (PI3K) and mammalian target of rapamycin in clinical development at HEC Pharm for the treatment of idiopathic pulmonary fibrosis.

Mechanisms of Action: PI3K Inhibitor,MTOR Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Sunshine Lake Pharma
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for HEC-68498

Countries in Clinic: China

Active Clinical Trial Count: 1

Highest Development Phases

Phase 1: Oncology Solid Tumor Unspecified

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

HEC68498-P-01

P1

Completed

Oncology Solid Tumor Unspecified

2021-02-26

34%

Recent News Events

Date

Type

Title